Metformin for Health & Longevity - Quick Reference Sheet

Metformin for Health & Longevity

Created on 08/07/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

A low-cost oral medication with a seventy-year record in blood sugar management. The strongest evidence stays there: lower blood sugar, better response to insulin, delayed onset of diabetes. Broader slowing of aging remains unresolved — corrected human data run against it, monkey data renew the case. Documented costs: digestive upset, vitamin B12 depletion, dampened gains from training. (Full Review)

Protocol

Longevity-oriented protocol
500 mg extended-release once daily, evening
Some titrate to 1,000–1,500 mg daily. No trial has compared low-dose against standard-dose for any aging endpoint: an inference from mechanism, not a validated regimen.
Standard glycemic protocol used by leading practitioners
500 mg daily, titrated to 1,000 mg twice daily
Initiation with the evening meal, increasing by 500 mg weekly as tolerated. Maximum licensed: 2,550 mg daily immediate-release, 2,000 mg daily extended-release.
Best time of day
Evening, with the largest meal
Targets overnight hepatic glucose production, exploits extended-release kinetics across the sleep period, and maximises the interval to morning training.
Time to effect
Glucose lowering
Days to 1–2 weeks
Begins within days; near-maximal in one to two weeks.
Full HbA1c response
~3 months
HbA1c reflects the preceding two to three months of blood sugar.
Weight effects
3–6 months
Where they occur. Any putative effect on biological aging would require years and cannot be observed by the individual.

Benefits

Contraindications
  • eGFR below 30 mL/min/1.73 m²
  • Initiation not recommended at eGFR 30–45 mL/min/1.73 m²
  • Acute or unstable heart failure with hypoperfusion (New York Heart Association Class IV)
  • Acute metabolic acidosis of any cause, including diabetic ketoacidosis
  • Severe hepatic impairment (Child-Pugh Class C) or active alcoholic liver disease
  • Known hypersensitivity
  • Sustained heavy alcohol intake
  • Untreated vitamin B12 deficiency, until repletion
  • Adults over 80 who have not had creatinine measured
  • Temporary withholding: acute illness with dehydration, sepsis, hypoxia, or shock; major surgery; iodinated contrast when eGFR is below 60
Key Interactions
  • Iodinated contrast media (iohexol, iodixanol, iopamidol, ioversol)
  • Carbonic anhydrase inhibitors (topiramate, acetazolamide, zonisamide, dichlorphenamide)
  • Renal cation transport inhibitors (cimetidine, dolutegravir, ranolazine, vandetanib, isavuconazole, trimethoprim, pyrimethamine, crizotinib)
  • Drugs that reduce renal perfusion (NSAIDs, ACE inhibitors, ARBs, loop and thiazide diuretics)
  • Alcohol
  • Insulin and insulin secretagogues (sulfonylureas, meglitinides)
  • Over-the-counter medications (cimetidine, ibuprofen, naproxen, nicotinic acid)
  • Supplements with additive glucose-lowering effects (berberine, chromium picolinate, alpha-lipoic acid, cinnamon extract, Gymnema sylvestre, bitter melon, fenugreek)
  • Goldenseal
  • Prolonged fasting, ketogenic diets, very-low-carbohydrate protocols
  • Intense endurance exercise

Risk & Side Effects

  • High: Gastrointestinal intolerance; vitamin B12 depletion
  • Medium: Blunted aerobic training adaptation; blunted resistance-training hypertrophy
  • Low: Lactic acidosis; suppression of thyroid-stimulating hormone; nitrosamine contamination in some extended-release products; hemolytic anemia and hepatic injury; paternal preconception exposure and birth defects
  • Speculative: Accelerated loss of muscle mass in metabolically healthy older adults; occlusion of exercise- and fasting-induced hormesis

Monitoring

Marker Target Why
eGFR >90 mL/min/1.73 m² Governs dosing and lactic acidosis risk
Serum vitamin B12 500–1,100 pg/mL Detects the drug's most common nutritional depletion
Methylmalonic acid <0.27 µmol/L Confirms functional B12 status when serum B12 is borderline
Homocysteine <9 µmol/L Reflects combined B12 and folate adequacy
HbA1c 4.9–5.4% Primary measure of the drug's glycemic effect
Fasting glucose 75–86 mg/dL Reflects overnight hepatic glucose output, metformin's main target
Fasting insulin 2–5 µIU/mL The earliest marker of the insulin resistance metformin addresses
HOMA-IR <1.0 Single summary index of insulin resistance and the strongest predictor of who benefits
High-sensitivity C-reactive protein <0.5 mg/L Tracks the chronic low-grade inflammation metformin is proposed to reduce
Mean corpuscular volume 82–89 fL Early signal of B12 or folate depletion before symptoms appear
Alanine aminotransferase <20 U/L (men), <17 U/L (women) Screens for the rare hepatic reaction and tracks fatty liver, a common co-indication
Thyroid-stimulating hormone 0.5–2.0 mIU/L Detects the drug's suppressive effect in people on thyroid replacement
Venous lactate <1.6 mmol/L Investigated only if symptoms suggest acidosis

Cadence: Kidney function and metabolic panel at 3 and 6 months, then annually — every 3 months below eGFR 45 mL/min/1.73 m² or with renally active co-medications. HbA1c, fasting insulin, HOMA-IR at 3 months, then every 6–12 months. Vitamin B12 at 12 months, then annually, with methylmalonic acid whenever serum B12 is below 400 pg/mL. Complete blood count annually. Cardiorespiratory fitness and body composition at baseline, then every 6–12 months.

Qualitative Assessment

  • Digestive tolerance: Stool frequency and form, cramping, nausea, and metallic taste, tracked daily during titration.
  • Training performance and recovery: Perceived exertion at fixed workloads, session quality, and recovery.
  • Strength and lean mass trajectory: Whether working loads progress on a stable training programme.
  • Neurological symptoms: Numbness, tingling, burning in the feet or hands, and changes in balance or gait.
  • Energy, cognitive clarity, and mood: Daytime energy, mental sharpness, and mood stability.
  • Sleep quality: Ease of falling asleep, overnight awakenings, and morning restedness.